Cipla rallies to 52-week high on Muhurat Trading day; leads NIFTY50 gains

At close, Cipla shares settled at ₹1,665 apiece, climbing 1.58%. It was the biggest contributor on the NIFTY50 index.

Over the past five trading sessions, shares of the pharma major have gained almost 7%, while rising 8% over the past month. The stock has surged more than 20% in six months. Since the beginning of the year, it has climbed 9%.

The company’s market capitalisation stands at ₹1.35 lakh crore.

Cipla to announce Q2 results on this date

Cipla has informed the stock exchanges that its board of directors will meet on October 30, 2025, to consider and approve the unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2025.

Here’s how the company performed in Q1

Cipla had posted a 10% growth in its consolidated net profit at ₹1,298 crore for the quarter ended June 30 of the current fiscal year as compared to ₹1,178 crore for the same quarter of the previous fiscal year.

The company’s total revenue from operations stood at ₹6,957 crore year-on-year (YoY) for the quarter under review as compared to ₹6,694 crore, marking an increase of 4%.

Cipla’s operating profit, or earnings before interest, taxes, depreciation, and amortisation (EBITDA), witnessed a growth of 3.6% at ₹1,778 crore as against ₹1,716 crore YoY. In Q1, the firm’s margin remained flat at 25.6% YoY.

Cipla’s One India Business delivered a growth of 6% YoY for the quarter, breaching the threshold of ₹3,000 crore for the first time ever in the opening quarter of any financial year.

The drugmaker’s US business delivered a quarterly revenue of $226 million, supported by traction in differentiated assets.

Revenue and development (R&D) investments of the drugmaker stood at ₹432 crore, or 6.2% of sales, driven by product filings and development efforts.

Cipla’s growth momentum for Africa business continued with overall revenue growth at 11% YoY in dollar terms. Its emerging markets and Europe also posted a healthy revenue growth of 8% YoY in USD terms.